RecruitingNCT06969755
Biomarkers and early treatment response in schizophrenia
About this title
Read the official source — NCT06969755Medication studyAges 18–35United States + Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 35 years.
- Listed locations
- Birmingham and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 4, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 180
- Sponsor
- Northwell Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT06969755
- Official title
Show the full official title
Biomarkers to Enhance Early Schizophrenia Treatment
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Birmingham, United States · La Jolla, United States · Belmont, United States
2 more locations
- Glen Oaks, United States
- Toronto, Canada
Questions about this study
Who is behind this study?
The study sponsor is Northwell Health.
Does this study involve medication?
Yes. The study involves medication, including aripiprazole, risperidone and clozapine.
Who can participate?
Listed age limits: 18 years to 35 years.
Is this study still recruiting?
The registry lists this study as recruiting.
